Achilles Therapeutics (NASDAQ:ACHL – Get Free Report)‘s stock had its “underperform” rating reaffirmed by investment analysts at Bank of America in a research note issued to investors on Thursday, Benzinga reports. Achilles Therapeutics Trading Down 7.6 % Shares of NASDAQ:ACHL traded down $0.07 during midday trading on Thursday, hitting $0.89. 209,674 shares of the stock […]
Related Keywords
United States , America , , Balyasny Asset Management , America Corp , Virtu Financial , Achilles Therapeutics Plc , Sei Investments Co , Achilles Therapeutics , Get Free Report , Asset Management , Street Group , Sei Investments , Therapeutics Plc , Achilles Therapeutics Daily , Nasdaq Achl , Bachl , Medical , Reiterated Rating , Bank Of America Co ,
vimarsana.com © 2020. All Rights Reserved.